Provider review
Collective review: membership costs and the evidence behind its calculator
Collective combines low medication prices with a separate annual membership. Its weight-loss calculator links a real observational study, but that study followed people who remained in another program for a year. Compare the complete fee structure and eligibility rules before treating a group average as an individual forecast.
Partner link — we may earn a commission. How we’re paid
Visit CollectiveOf Collective’s 2 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
The calculator links observational evidence, but it cannot forecast an individual result. Budget for the annual membership as well as medication.
Worth trusting if
- You want published medication and membership prices before intake
- You value access to clinician messaging and nutrition support
- You can distinguish observational outcomes from an individual forecast
Be skeptical if
- Your state is one of the six excluded in the current FAQ
- You are budgeting only from the medication headline
- You expect the calculator to predict your own outcome
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Collective
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide — Advertised at $59 a month, which does not include the mandatory $199 annual membership.
- Compounded tirzepatide — Advertised at $69 a month, the same price at any dose, and again before the $199 annual membership.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not Collective's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Collective’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Semaglutide is a GLP-1 medication that helps reduce hunger, increase feelings of fullness, and support weight loss. In clinical studies, participants lost an average of about 15% of their body weight when combined with diet and lifestyle changes.”
Read on the Collective site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in adults with obesity or overweight and a weight-related condition; mean weight reduction of 14.9% on semaglutide 2.4mg alongside lifestyle intervention.
This captures the September 15% claim, which matched STEP 1 after rounding. On October 13 the homepage instead says about 18%; the earlier assessment does not apply to that revised claim. STEP 1 tested an approved product, not the compounded preparation supplied here.1
Compounded tirzepatideTirzepatide · Compounded (503A)Claim reaches past the trials
“See what each medication achieved in real-world studies. Average weight loss seen in real-world studies 46 lbs. Potential weight after treatment 154 lbs (Based on real-world results of 23% body weight). In a real-world study, where most patients used compounded tirzepatide, people averaged about 23% of body weight over 12 months.”
Read on the Collective site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks, adults with obesity or overweight without diabetes. Mean weight reduction of 20.9% at 15mg in the treatment-regimen estimand, around 22.5% in the efficacy estimand. The trial used branded tirzepatide; no randomized trial of a compounded preparation has been published.
The current calculator links the IVIM retrospective study of 1,166 one-year completers (reference 4). Our former missing-source criticism is superseded. Its observational design and another provider’s population limit use as a forecast for a new Collective patient; a higher mean than a different trial is not itself evidence of an inaccurate study.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named, and no clinician, medical director or advisory name is published anywhere on the marketing site. The operating entity is Health For Everyone Inc., trading as CollectiveOS. One gap worth flagging for anyone reading the legal pages: the Terms and Privacy Policy describe the platform as covering "GLP-1s, peptides, and related products", and no peptide product is published for sale anywhere on the site — so the contract is written wider than the catalog.
Read on the Collective site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
The current homepage makes a third-party testing claim, but this review has not verified a described testing regime or batch-specific certificate. Its calculator now links an observational study, while the semaglutide wording has changed to 18%; see the current evidence discussion below.
Read on the Collective site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
The October 13 homepage FAQ states availability in 44 states and excludes Alabama, California, Louisiana, Massachusetts, Mississippi and Washington. Confirm current clinical and product eligibility before payment.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The entity is Health For Everyone Inc., doing business as CollectiveOS.
Named as outside that footprint
Read on the Collective site, October 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
Assessment
What holds up, and what does not
- Current calculator links the study behind its 23% figure.
- Public FAQ identifies the annual membership and trial deadline.
- The calculator warns that an average is not a prediction.
- The medication headline excludes annual membership.
- The cited cohort describes people who completed a year of another program.
- The revised 18% semaglutide claim does not match STEP 1’s 14.9% result.
Verdict
The bottom line
The membership and medication charges need to be compared together. Collective now supplies a study link for its calculator; the study design, rather than a missing citation, is the important limitation. Confirm state eligibility and the cancellation deadline before paying.
Opens Collective's website. A link is not a recommendation to take anything.
What joining costs
Checked October 13, 2026: the public offer is $59 a month for compounded semaglutide or $69 for compounded tirzepatide, plus $199 annual membership after a 21-day membership trial. Medication is charged during that trial. At unchanged rates, twelve medication payments plus one membership equal $907 or $1,027; those are comparison estimates, not a personalized quote. 3
The seller describes account cancellation before the trial ends and a refund if a clinician declines treatment. Canceling future membership is different from recovering an annual fee already paid or returning dispensed medicine. Ask which deadline applies to your next medication order.
Full analysis — 3 more sectionsThe calculator has a source · The semaglutide claim has changed · Check eligibility before comparing prices
The calculator has a source
Our September review described its 23% figure as unsourced. The current page links Duncan and colleagues' IVIM study. That was a retrospective analysis of 1,166 people who completed at least 52 weeks of treatment, rather than a randomized trial of Collective patients. 4
That distinction matters more than whether 23% is above a result from another trial. Different populations, treatment support and retention rules can produce different averages. Selecting people who remained in care for a year does not establish what every new starter will achieve. The calculator itself warns that the result is not a personal prediction; take that warning seriously.
The semaglutide claim has changed
The current product description uses about 18%, replacing the roughly 15% wording we reviewed previously. STEP 1 reported 14.9% over 68 weeks, so our former unqualified praise of a match to that trial no longer holds. 1 Ask which study, dose and population support the revised figure. Neither trial results for an approved product nor observational outcomes establish equivalence of the exact compounded preparation you receive.
Check eligibility before comparing prices
The public FAQ excludes Alabama, California, Louisiana, Massachusetts, Mississippi and Washington. It describes clinician messaging and nutrition support, but those service promises are not evidence of a response time we have tested. Confirm the dispensing pharmacy, your prescribed formulation and follow-up arrangements before enrolling. The older per-record dates elsewhere on this review remain the dates those individual facts were checked.
Questions
Frequently asked questions
Is the calculator unsourced?
It now links the IVIM study. Our earlier description is superseded. The important limits are its retrospective design, one-year completer population and use of another care program.
What does membership add to the medication price?
The October public offer adds $199 a year after a 21-day membership trial. Medication is paid separately during the trial. Confirm cancellation and medication-order deadlines before enrolling.
Can I use Collective in every state?
The October FAQ excludes Alabama, California, Louisiana, Massachusetts, Mississippi and Washington. Availability and clinical eligibility should be checked before payment.
Glossary
Key terms
Show definitions
- Real-world study
- An observational look at what happened to patients in ordinary care, rather than a randomized trial. It can be informative and it cannot control for who chose the treatment, so its numbers are not interchangeable with trial results.
- Efficacy estimand
- An analysis estimating the effect if participants remained on assigned treatment. The treatment-regimen estimand includes outcomes regardless of stopping treatment; the two answer different questions.
Compare
Others selling what Collective sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Collective is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Collective's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 4 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 participants, mean weight reduction 14.9% alongside lifestyle intervention. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 participants, 20.9% in the treatment-regimen estimand and around 22.5% in the efficacy estimand, using branded tirzepatide. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
- Publisher (2026). Collective public offer, eligibility and calculator; checked October 13. Public primary source. the Collective site
- Duncan J, Stevens PL, Bigby E, et al. (2025). Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol. Obesity Pillars; published online November 29, 2025; March 2026 collection. https://pubmed.ncbi.nlm.nih.gov/41438798/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.